Please assess the completion status of the following clinical trial:

Trial Title: Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Radiological suspicion of a unilocular malignant glioma with distinct ring- or garland-shaped contrast agent-accumulating tumour structures and a core of reduced intensity in the MRI (central necroses) with no significant non-staining tumour tissue (exclusion of a secondary malignant glioma).~* Indication for surgical tumour resection. If radical resection is planned, the location of the contrast agent-accumulating tumour should allow complete resection.~* First operation of the tumour, no other tumour-specific pretreatment~* Karnofsky at least 70 %~* Patient's written informed consent~* Age 18-72 years~Exclusion Criteria:~* Tumour location in the midline, basal ganglia, cerebellum or brain stem~* More than one contrast agent-accumulating lesion unrelated to the primary tumour or extracerebral metastases~* Porphyria, hypersensitivity to porphyrins~* Renal insufficiency: Creatinine \> 2.0 mg/dl~* Hepatic insufficiency: Bilirubin \> 3 mg/dl~* Quick test \< 60 %~* gamma-GT \> 70 U/I~* Malignancies other than basaliomas~* Existing or planned pregnancy or lactation, or inadequate contraception~* Simultaneous participation in another clinical trial or participation in another clinical trial in the 30 days preceding randomisation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- 5-aminolevulinic acid (Type: EXPERIMENTAL): None
- Conventional resection (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).